A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Until recently, options for second-line chemotherapy in CRPC have included docetaxel
retreatment, mitoxantrone, or other chemotherapies, without proven clinical benefit. In
2010, a Phase 3 second-line chemotherapy trial (TROPIC) showed a survival advantage for
cabazitaxel, a semi-synthetic taxane selected to overcome the emergence of taxane
resistance, when compared to mitoxantrone.
Clusterin is a stress-activated cytoprotective chaperone up-regulated by a variety of
anti-cancer therapies that confers treatment resistance when over-expressed. Inhibition of
clusterin expression using custirsen has been shown to enhance tumor cell death following
treatment with chemotherapy.
The clinical activity of custirsen in combination with the taxane docetaxel has been shown
in two Phase 2 studies. Given the results observed using a taxane as either first-line or
second-line chemotherapy in CRPC, combination with custirsen may decrease taxane resistance
and enhance the survival benefit of taxane therapy. Thus, a combination of custirsen with
cabazitaxel may further enhance survival in second-line taxane chemotherapy for CRPC.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Survival
To determine whether the survival for patients randomized to the investigational arm (cabazitaxel/prednisone plus custirsen) is consistent with longer survival as compared to patients randomized to the control arm (cabazitaxel/prednisone).
3.4 years
No
Thomasz Beer, MD
Principal Investigator
Oregon Health & Science University, Portland, Oregon
United States: Food and Drug Administration
OGX-011-12
NCT01578655
August 2012
December 2015
Name | Location |
---|---|
H. Lee Moffitt Cancer Center and Research Institute | Tampa, Florida 33612 |
Washington University School of Medicine | Saint Louis, Missouri 63110 |
University of California Davis Medical Center | Sacramento, California 95817 |
Hartford Hospital | Hartford, Connecticut 06102-5037 |
Cooper University Hospital | Camden, New Jersey 08103 |
Rocky Mountain Cancer Center | Denver, Colorado 80218 |
Cancer Centers of the Carolinas | Greenville, South Carolina 29605 |
Florida Cancer Specialists | Fort Myers, Florida 33901 |
Georgia Cancer Specialists, P.C. | East Point, Georgia 30344 |
South Carolina Oncology Associates | Columbia, South Carolina 29201 |
SUNY Upstate Medical University | Syracuse, New York 13210 |
Helen F. Graham Cancer Center | Newark, Delaware 19713 |
California Pacific Medical Center Research Institute | San Francisco, California 94115 |
Oncology Hematology Care, Inc. | Cincinnati, Ohio 45219 |
Blumenthal Cancer Center | Charlotte, North Carolina 28203 |
Virginia Cancer Institute | Richmond, Virginia 23230 |
Oregon Health and Science University | Portland, Oregon 97201 |
Sharp Health Care | San Diego, California 92123 |
The West Clinic | Memphis, Tennessee 38120 |
The Center for Hematology-Oncology | Boca Raton, Florida 33486 |
Saint Francis Hospital and Medical Center | Hartford, Connecticut 06105 |
Chattanooga Oncology and Hematology Associates | Chattanooga, Tennessee 37404 |
Cancer Center of Kansas | Wichita, Kansas 67214 |
Tennessee Oncology, PLLC | Clarksville, Tennessee 37043 |
Prostate Oncology Specialists | Marina Del Rey, California 32589 |
Baptist Hospital East | Louisville, Kentucky 40207 |
Monter Cancer Center | Lake Success, New York 11042 |
Boston University Medical Center | Boston, Massachusetts 02118 |
University of Michigan Health System | Ann Arbor, Michigan |
Moses Cone Regional Cancer Center | Greensboro, North Carolina 27403 |
The Mark H. Zangmeister Center | Columbus, Ohio 43219 |
Virginia Cancer Specialists, PC | Fairfax, Virginia 22031 |
Frontier Cancer Center and Blood Institute | Billings, Montana 59102 |
Urology Cancer Center and GU Research Network | Omaha, Nebraska |
Center for Cancer and Blood Disorders, PC | Fort Worth, Texas |
Piedmont Healthcare Research Institute | Atlanta, Georgia |
Albert Einstein Medical Center | Bronx, New York |